-- Earnings Flash (ATHX) ATHERSYS Posts Q1 Revenue $2.9M, vs. Street Est of $1.38M
8:03AM ET 5/06/2022 MT Newswires...
Quotes Snapshot > ATHX
Athersys Inc ATHX:NASDAQ
Last Price$0.76NASDAQ Closing Price as of 4:00PM ET 5/19/22
Today's Change+0.04(6.24%)
Bid (Size)$0.75 (2)
Ask (Size)$0.78 (19)
Day Low / High$0.68 - 0.78
Volume1.7 M
Read more news Recent News
Athersys Files $250 Million Mixed Shelf
4:18AM ET 5/06/2022 MT NewswiresAthersys (ATHX) on Thursday filed a shelf registration statement for the potential sale of up to $250 million of its securities from time to time. The...
Top Premarket Decliners
8:00AM ET 4/12/2022 MT NewswiresMyovant (MYOV) shares slumped 21% after the US Food and Drug Administration flagged certain deficiencies in the company's supplemental new drug application...
Top Premarket Decliners
8:10AM ET 4/04/2022 MT NewswiresCuris (CRIS) shares slumped 32% after the company said the US Food and Drug Administration placed the company's leukemia drug on partial clinical hold....
View all Commentary and Analysis
Athersys: Focus On Stroke
9:40AM ET 5/04/2022 Seeking AlphaAthersys - Hero Or Zero Opportunity
10:56AM ET 4/18/2022 Seeking AlphaAthersys, Inc. (ATHX) CEO Daniel Camardo on Q4 2021 Results - Earnings Call Transcript
8:47PM ET 3/15/2022 Seeking AlphaAthersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
2:34PM ET 1/20/2022 Seeking AlphaCompany Profile
Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 05/12/2022 424B5 |
| Chief Executive Officer & Director | Daniel A. Camardo |
| President & Chief Operating Officer | William B. J. Lehmann |
| Chief Financial & Accounting Officer | Ivor MacLeod |
| Director, Chief Scientific Officer & Executive VP | John J. Harrington |
Company Highlights
| Price Open | $0.72 |
| Previous Close | $0.71 |
| 52 Week Range | $0.46 - 1.81 |
| Market Capitalization | $190.6 M |
| Shares Outstanding | 252.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.35 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -981.52% |
| Return on Equity | -429.24% |
Analyst Ratings as of 11/18/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |